The Rho-associated kinase (ROCK1) inhibitor Y27632 emerged from an in vitro screen for molecules that reduce polyglutamine toxicity and subsequently was shown to reduce huntingtin toxicity and aggregation in cellular and drosophila models of HD [6, 7] and to enhance both proteasomal degradation of Htt and macroautophagy [8, 9]. Here, ROCK1 is linked to Huntington disease.